Candel Therapeutics to present NSCLC aglatimagene besadenovec study data at SITC 2026
CADL•Candel Therapeutics plans two poster presentations at SITC’s 41st Annual Meeting, November 4-8, 2026, in Phoenix. One will cover NSCLC analyses linking aglatimagene besadenovec with immune activation tied to improved survival after checkpoint inhibitor failure.
1. Planned poster presentations
Candel Therapeutics set two poster presentations for SITC’s 41st Annual Meeting, scheduled for November 4-8, 2026, in Phoenix. One will present NSCLC analyses linking aglatimagene besadenovec with immune activation tied to improved survival after checkpoint inhibitor failure; the other will outline phase 1b findings for linoserpaturev combined with VEGF blockade in recurrent glioblastoma.
